SCHEMBL839205

SCHEMBL839205

CCCCC(O)C(=O)Nc1ccc(C)cn1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
RAB9A P51151 5/20 0.54
MAPT P10636 2/20 0.54
ADRA2A P08913 2/20 0.49
ADRA2B P18089 2/20 0.49
ADRA2C P18825 2/20 0.49
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPK1 P28482 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
NPC1 O15118 3/20 0.47
POLB P06746 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL838669 0.85 RAB9A (0.60) TSHRRAB9AMAPTADRA2AADRA2B
SCHEMBL838394 0.85 RAB9A (0.60) TSHRRAB9AMAPTADRA2AADRA2B
SCHEMBL27819829 0.85 RAB9A (0.50) TSHRRAB9AMAPTADRA2AADRA2B
SCHEMBL838343 0.82 RAB9A (0.53) RAB9AMAPTKDM4EALDH1A1L3MBTL1
SCHEMBL839447 0.82 RAB9A (0.53) RAB9AMAPTADRA2AADRA2BADRA2C
SCHEMBL838342 0.82 RAB9A (0.53) RAB9AMAPTKDM4EALDH1A1L3MBTL1
SCHEMBL839352 0.82 TSHR (0.46) TSHRRAB9AMAPTKDM4EMAPK1
SCHEMBL838587 0.81 RAB9A (0.51) RAB9AMAPTADRA2AADRA2BADRA2C
SCHEMBL838393 0.81 RAB9A (0.51) RAB9AMAPTADRA2AADRA2BADRA2C
SCHEMBL838720 0.80 RAB9A (0.53) RAB9AMAPTADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
US-8143263-B2 Therapeutic agents ASTRAZENECA AB (SE) 2012-03-27 US disclosed
CN-102171213-A Pyrazolo [3, 4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity ASTRAZENECA AB 2011-08-31 CN disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
US-20100093757-A1 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-04-15 US disclosed
WO-2010015849-A2 THERAPEUTIC AGENTS 414 ASTRAZENECA AB (SE) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093757-A1 THERAPEUTIC AGENTS 414 GCK, GCKR, GPR119 TSHR 1264/4885RAB9A 3239/4885MAPT 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.